Biophotonics Market Size & Share Report, 2025 - 2034

 Biophotonics Market Size

The global biophotonics market size was valued at USD 76.1 billion in 2024 and is estimated to grow at CAGR of 11.3% to reach USD 220.1 billion by 2034. Rising technological innovation in the medical sector coupled with the rapid emergence of nanotechnology are the major factors contributing to the growth of the market.

As nanotechnology enables unprecedented control over light-matter interactions at the nanoscale, which helps in improving the performance of diagnostic and therapeutic tools its rapid emergence is the key factor driving the biophotonic market. For instance, according to GMI analysis the global nanotechnology in medical devices market size was valued at USD 4.7 billion in 2024 and is expected grow at a CAGR of 9.2% from 2025 to 2034. By employing nanomaterials including metallic nanoparticles and quantum dots, biophotonic devices enable higher sensitivity and specificity for sensing biomarkers as well as for tissue imaging. All this is resulting in detection at earlier disease stages and also with more specific treatments.

The global aging demographic is creating a significant opportunity for the biophotonics market. As per the WHO data world's population over 60 years will double from 12% to 22% between 2015-2050. Moreover, according to WHO  1 in 6 people in the world will be aged 60 years or over by 2030. As aging consumers become more in need of advanced diagnostic and monitoring products, companies stand to meet a rising demand for non-invasive, high-accuracy healthcare products. By targeting age-related diseases like cancer and cardiovascular disease, companies can benefit from a strong market segment that requires ongoing innovation and enhanced patient care.
Lifestyle diseases, including diabetes, obesity, and cardiovascular disorders, are on the rise, creating a substantial market push for advanced biophotonic solutions. For instance, according to WHO Diabetes and kidney disease caused over 2 million deaths and around 11% of cardiovascular deaths were caused by high blood glucose in 2021. These conditions call for proactive management by early diagnosis and routine monitoring services that biophotonic technologies are capable of providing.

Manufacturers should incorporate nanotechnology into biophotonic devices to increase diagnostic accuracy and therapeutic efficacy, in order to meeting the growing needs for cutting-edge medical technologies. Moreover, they should focus on developing technologies which facilitate early detection and monitoring of lifestyle diseases, such as diabetes and obesity, to tap rising market segments.

Biophotonics Market Trends

• Integration of artificial intelligence (AI) and machine learning (ML) in biophotonics industry is on the rise. These technologies helps in optimizing processes related to imaging data interpretation which enables quicker and more reliable diagnoses. AI-driven biophotonics techniques such as Raman spectroscopy integrated with machine learning have shown great success in the recent studies. For example, in 2024, University of Edinburgh researchers were able to detect early breast cancer with a 98% accuracy. This system identified tiny chemical changes present in blood tests that other methods fail to consider.
   
• The biophotonics sector is noticing transformative advancements, particularly with the development of non-invasive imaging techniques that significantly enhance both life science research and patient care. A prime example is the advent of near-infrared II (NIR-II) fluorescence imaging, which offers deeper tissue penetration and higher resolution compared to earlier imaging modalities. This technology has become instrumental in cancer surgeries by facilitating precise tumour localization and delineation of tumour margins, thereby improving surgical accuracy and patient outcomes. Apart from oncology, NIR-II fluorescence imaging broadens the scope of its application in various fields of medicine such as enhancing anatomical mapping and complex biological structure visualization. The incorporation of NIR-II fluorescence imaging into clinical practice highlights the need for advancing biophotonic technologies, which offers abundant prospects for healthcare innovation and investment.
   
• Biophotonics industry is also aided by a rise in strategic partnerships and research expenditure within industry, academia, and government laboratories. For example, in November 2023, at the Society for Neuroscience (SfN) annual meeting, ZEISS Group revealed cutting-edge imaging technology that encompasses next-generation fluorescence microscopy methods These technologies allow scientists to visualize cellular structures and processes at higher clarity and precision than ever before. Some of these innovations are improved resolution capability and increased imaging speed, which are essential to image dynamic biological processes in real time. Such collaborations are instrumental in driving technological advancement and shortening time-to-market for emerging diagnostic technology. Joint collaborations are helping bring together resources, reduce expenses, and reducing the risks involved with new product creation. This is not only leading to ongoing innovation in biophotonic technology but enhancing overall firm competitiveness for companies that are operating within this dynamic marketplace.
   Based on technology, the market is divided into In-Vitro and In-Vivo.

   

  • The In-Vitro market is growing at the significant rate and is expected to reach the market size of USD 89.6 billion in 2034. Advancements in diagnostic and analytical technologies is the major factor responsible for growth in the segment. Integration of automation and AI-based analysis in in-vitro platforms enables to streamline workflows, reduced error rates, and optimized laboratory operations which is the major factor contributing to the segment growth. Moreover, increasing demand for early disease detection and personalized medicine is also expected to boost the market.
     
  • The In-Vivo market held the largest share of 57 % in the year 2024 and is expected to continue its domination till the forecast period. Technological advancements, especially in the field of optical imaging and laser diagnostics, have greatly enhanced the accuracy and safety of such treatments. This has resulted in higher clinical uptake for uses like cancer detection at early stages, supported surgeries, and tracking of physiological processes which is driving the market.

World Biophotonics Research Awards
Visit: biophotonicsresearch.com
Nominate Now: https://biophotonicsresearch.com/award-nomination/?ecategory=Awards&rcategory=Awardee 

Optical Filter Orientation Dictates System Effectiveness

When integrating an optical filter into the design of an optical system, it is vital to understand the angle of incidence (AOI) and cone half angle (CHA) requirements on the filters to optimize functionality for a wide variety of life sciences and biomedical research applications. The larger the deviation from the designed AOI, the greater the peak wavelength shift and the overall transmission drop.

Increasing the AOI blue shifts the transmission peak toward shorter wavelengths, while reducing the AOI red shifts the transmission peak toward longer wavelengths. In wavelength-dependent application spaces, such as fluorescence spectroscopy and nuclear magnetic resonance, a misaligned filter with too much red/blue shift would be severely detrimental to experimental results or device readings.

The larger the CHA of the incoming light, the greater the loss in peak transmission and the greater the peak broadening, which can allow unwanted wavelengths adjacent to the design wavelength to pass through the filter.

Certain design techniques can be implemented by system developers to decrease a filter’s sensitivity to the effects of AOI and CHA. This article discusses the importance of considering angular effects on filter performance in optical system design, as well as potential mitigation strategies.

Impact of angle of incidence

The AOI is defined as the angle between a collimated beam incident on the optic and the surface normal (perpendicular direction) of the filter’s first surface (Figure 1). Altering the AOI from a filter’s specified nominal value will shift the peak transmission toward shorter wavelengths when increasing AOI, and toward longer wavelengths when decreasing AOI. In a simple case with a 0° AOI, this occurs because the optical path difference between reflections off the first and second surfaces of a coating layer shortens, causing interference to favor shorter wavelengths (Figure 2a and 2b). This shift toward shorter wavelengths is known as a blue shift.

Along with the shift toward shorter wavelengths, increasing AOI typically reduces transmission efficiency, creating a noticeable reduction in overall light throughput. At extreme angles deviating from the specified AOI, the entire spectral shape deforms, and the filter’s ability to perform as specified becomes highly compromised (Figure 2, top). This negatively affects overall system throughput and performance. This deterioration can be mitigated by optimizing the optical coating design (Figure 2, bottom) to block and pass specific wavelengths.

As AOI strays more from its optimal angle, the filter’s spectral profile distorts further and creates sidebands or secondary peaks, which can produce inaccurate measurements. Unwanted wavelengths may be passed and desired ones blocked, which affects data collection and accuracy. Thus, considering the AOI when constructing a system is crucial. In some cases, a custom coating design can help to avoid spectral degradation and provide optimal performance where accuracy is paramount, as in the case of virus detection.

During the COVID-19 pandemic, rapid tests were built using gold nanoparticles (AuNPs). These tests detect viral RNA or proteins using spectral shifts, with a red shift (toward longer wavelengths) occurring when nanoparticles aggregate or when the local refractive index increases due to molecular binding. A blue shift (toward shorter wavelengths) can occur if nanoparticles disperse or if the surrounding medium becomes optically less dense.

A misaligned filter in the spectroscopy device reading the samples could lead to false positives or negatives and propagate public health scares. An understanding of AOI directly aided virus detection in the early stages of the pandemic, when fear and tensions were high.

Typical AOI specifications are 0°, with a ±5° tolerance, but designs can sometimes specify other AOIs. Difficulty arises with use cases requiring larger AOI ranges. Ranges exceeding ±10° require significantly more design effort and thicker coating stacks, and they also lead to increased costs. For example, as shown in Figure 2a, a 1064-nm light source (commonly used for research) at 16° AOI will no longer pass through the filter.

When a large AOI range cannot be avoided, absorptive filters, such as color glass, may be a suitable alternative to filters with optical coatings, as their spectral performance is insensitive to the AOI and CHA of the incoming light. Absorptive filters incorporate dyes to select desired wavelengths, rather than thin-film coatings. However, thin-film interference filters typically have better spectral performance, meaning they offer higher transmission and blocking, and often at more precise wavelengths. The spectral range can be (almost) freely designed for coated filters.

For color glass, the optical absorption properties of dyes or other chemical elements dictate the optical spectra, thus rendering custom options limited. If possible, thin-film interference is preferred for its higher performance and wavelength specificity. Building on the COVID example, a virus detector that needs highly specific blocking/passing regions should opt for thin-film interference. However, if the AOI must be compromised, absorptive filters offer helpful AOI flexibility, such as in common laser beamsplitting setups.

World Biophotonics Research Awards
Visit: biophotonicsresearch.com
Nominate Now: https://biophotonicsresearch.com/award-nomination/?ecategory=Awards&rcategory=Awardee 

Biophotonic probes for bio-detection and imaging

 The rapid development of biophotonics and biomedical sciences makes a high demand on photonic structures to be interfaced with biological systems that are capable of manipulating light at small scales for sensitive detection of biological signals and precise imaging of cellular structures. However, conventional photonic structures based on artificial materials (either inorganic or toxic organic) inevitably show incompatibility and invasiveness when interfacing with biological systems.

The design of biophotonic probes from the abundant natural materials, particularly biological entities such as virus, cells and tissues, with the capability of multifunctional light manipulation at target sites greatly increases the biocompatibility and minimizes the invasiveness to biological microenvironment. In this review, advances in biophotonic probes for bio-detection and imaging are reviewed. We emphatically and systematically describe biological entities-based photonic probes that offer appropriate optical properties, biocompatibility, and biodegradability with different optical functions from light generation, to light transportation and light modulation.

Three representative biophotonic probes, i.e., biological lasers, cell-based biophotonic waveguides and bio-microlenses, are reviewed with applications for bio-detection and imaging. Finally, perspectives on future opportunities and potential improvements of biophotonic probes are also provided.Sensitive detection of biological signals and precise observation of pathological changes are of great importance for the early diagnosis and treatment of infectious diseases, cancer, and other health disorders. However, owing to the low quantity of biochemical signals and complex microenvironment in biological systems, the detection of the targets of interest is challenging. Fortunately, the prosperous development of optical and photonic technologies in recent years provides many choices for optical detection and imaging, holding great promises for real-time visualization of biological signals in complex biological structures and processes.

Optical detection exploits optical responses, such as light absorption, scattering, fluorescence, and reflectance, induced by biophysical/biochemical changes for bio-identification and disease diagnosis3. Due to the inherently label-free nature, optical detection is a powerful alternative to conventional detection techniques (e.g., mass or electrochemical)With optical detection techniques, real-time signals of a wide range of biological test samples (from molecular biomarkers to pathogens and cells, and even to tissues and organs) can be obtained in a non-invasive manner with high-sensitivity and high-resolution To date, optical detection and imaging have been demonstrated to be one of the most powerful technologies for detection of biological signals and for diagnosis .

For a precise and flexible optical detection in a biological microenvironment, photonic probes with micro/nanostructures are always desirable. For this purpose, the selection of appropriate optical materials is certainly crucial, since the probing performance largely depends on their chemical and mechanical properties, optical functionalities as well as biological performances.

To date, the most commonly used materials for the assembly of versatile photonic components and photonic probes are mainly based on inorganic materials such as silica glass, or organic polymers such as polymer nanowires. Because of their excellent optical properties, such as high transparency and suitable mechanical strength, these materials have been applied for nanophotonic integrated devices in diversified fields of application. For example, optical waveguides based on silica optical fibers have been widely studied and were even used for implantations in animal bodies, particularly fiber-optic implants in the brain for optogenetic studies.

 However, the main disadvantage of these photonic components based on traditional materials is low biocompatibility and biodegradability, which greatly limit their potential in biomedical applications. High biocompatibility of a material is a fundamental requirement for in vivo applications, which demands the absence of toxicity and low health threat to the living systems29. Moreover, high biocompatibility also refers to the biofunctionalities that the implants can perform their expected functions in vivo. Additionally, biodegradability is another essential requirement, since the materials can be degraded and metabolized by the body without the need for additional operations to remove the implants.

With abundant natural biomaterials and biological entities, Mother Nature always inspire us to design photonic structures and probes to manipulate light. Indeed, living cells and microscopic organisms as well as their derivates such as DNA, proteins, silk and cellulose et al., show different capabilities to interact with light, and can further serve as different photonics devices such as waveguides, microlenses, gratings, and even lasers. These natural biomaterials and biological entities hold huge promise for creation of new photonic probes for bio-detection, imaging, and therapeutic applications.

They inherently possess excellent biological performances, including noninvasiveness, high biocompatibility, biodegradability, and resorbability. Moreover, another interesting feature of biological entities such as virus, cells and tissues is their ability to serve simultaneously as optical devices and diagnostic specimen, which facilitate further real-time detection and imaging in biocompatible microenvironments.

Therefore, instead of bio-derived materials and biomolecules (such as proteins and nucleic acids), biophotonic probes introduced in this review are mainly focused on large biological entities, such as virus, bacteria, fungi, algae, mammalian cells and tissues. By translating biological principles into man-made designs, these biophotonic probes offer a seamless interface between optical and biological worlds.

World Biophotonics Research Awards
Visit: biophotonicsresearch.com
Nominate Now: https://biophotonicsresearch.com/award-nomination/?ecategory=Awards&rcategory=Awardee 

Internationally Renowned Biophotonics Researcher Secures Award to Develop New Medical Diagnostics and Treatment Tools

 Professor Stefan Andersson-Engels has been awarded €5.3 million through the SFI Research Professorship Programme, which will underpin the Biophotonics Group at Tyndall National Institute for the next five years. The funding will be used to advance the fundamental understanding of biophotonics science, the application of light-based technologies to life sciences and medicine.

This award will foster the development of new diagnostic and guidance tools to meet proven clinical needs. These will be implemented in the clinical setting of neonatology, neurosurgery, orthopaedics, and the GI tract, as well as oral cancer screening, and will be guided by 20 clinical and pre-clinical collaborators. The award aims to provide better healthcare and outcomes for patients, and to grow economic activity through the commercialisation of the resulting technologies. This will be achieved through partnerships with existing MedTech companies.

Principal Investigator at the IPIC SFI Research Centre for Photonics, Prof Andersson-Engels and his team have already created two start-up companies, one of which was in partnership with the National Cancer Centre in the Netherlands. The team has also transferred technologies to companies in the areas of cancer boundary detection and the monitoring of babies during childbirth.

The objective of Prof Andersson-Engels’ project is to use the unique properties of light, a safe, non-invasive method for humans that can accurately detect specific cells, for diagnostic purposes such as gastrointestinal diagnostics for malignancies and inflammatory bowel diseases, in-vivo oral cancer delineation and diagnosis. As light can only penetrate short distances into tissue, Prof Andersson-Engels will seek to address this challenge, and aim to facilitate light-based diagnostics and therapy deep inside the body, permitting use for many more diseases.  

Commenting on the award, Prof Andersson-Engels said: “I am delighted to be continuing our important work with the talented team across Tyndall, UCC, and IPIC. With the medical devices sector in Ireland recognised as one of the five emerging global hubs, it is an exciting time for the Biophotonics Group to forge close collaborations with companies, clinicians and research centres for the faster development and deployment of more accurate, less invasive diagnostic treatment methods for cancer and other diseases.”

Prof Andersson-Engels has an impressive track record, receiving several prizes for his research achievements, and his work on the development and commercialisation of technology has been critical to ensuring that patients will benefit from the results of scientific research. His pioneering work in the area of ALA-PDT (Photodynamic therapy) using the topical application of aminolevulinic acid (ALA), a photosensitizing agent for the treatment of non–melanoma skin cancer is currently one of the first lines of treatment at most skin cancer clinics around the world.

Welcoming the announcement, Deputy Director General of Science Foundation Ireland, Dr Ciarán Seoighe, said: “Recruiting and retaining world-leading scientific talent to Ireland is a key priority for SFI in partnership with our higher education institutions. Prof Andersson-Engels’ exceptional international track record will help to drive Ireland’s position at the forefront of photonics research. His work will contribute to improving the health and wellbeing of people by the invention and application of new technologies, as well as boosting industry engagement. We wish him every success with his research programme."

Surgical Oncologist, Head of Medical Affairs and Research, Centre for Early Cancer Detection at The Netherlands Cancer Institute, Professor Theo Ruers said: “We at The Netherlands Cancer Institute, have established a very strong and fruitful collaboration with the Biophotonics@Tyndall team over the last few years throughout the first phase of the Professorship Award. Our complementary skill sets have led to a spin-off company, multiple publications, and patents as well as collectively attracting EU and Health Holland funding. This collaboration is a win-win for both parties, and we expect the coming phase to be even more productive and impactful.”

Director of IPIC, the SFI Research Centre for Photonics, Professor Paul Townsend concluded: “This award further strengthens IPIC’s outstanding research team by providing the scientific vision and knowledge to steer existing photonic device integration towards innovative new applications in the biomedical areas. Furthermore, by continuing this world-class biophotonics research programme at IPIC and Tyndall, we can underpin strong collaborative partnerships with other Science Foundation Ireland Research Centres through projects that will present huge opportunities at a global level and again raise Ireland’s research credentials in the biomedical space.”

World Biophotonics Research Awards
Visit: biophotonicsresearch.com
Nominate Now: https://biophotonicsresearch.com/award-nomination/?ecategory=Awards&rcategory=Awardee 

Advances in biophotonic sensors: Revolutionizing medical diagnostics and research

 Biophotonic sensors and systems are optical devices developed to deliver point-of-care diagnostics for medical practitioners and health researchers. They allow researchers to detect, sense, identify, and understand biological systems at the cellular/subcellular level, allowing them to gain a deeper understanding of biological processes, conditions, and molecular changes.

Biophotonics is an emerging field demonstrating rapid growth, and optical designers and researchers are persistently developing new ways of capturing high-quality imaging, increased sensitivity detection, and more detailed analysis. Photonics technologies power medical advances like disease diagnosis, food and water safety, and drug efficacy testing. This article presents examples of biophotonic breakthroughs and how they are already making a difference across medical diagnostics and research.

Lab-on-a-chip point-of-care biophotonic sensors

Low-cost point-of-care biosensors that can deliver laboratory-quality results within minutes are making it possible to diagnose a disease early on and efficiently. This eliminates the need for expensive laboratory equipment, prolonged waiting times, and large laboratories.

For example, the lab-on-a-chip biosensors developed in response to the global COVID-19 pandemic helped combat the virus. The early spread of the disease was, in part, a result of inefficient testing protocols, and health researchers across the world worked hard to find a quick, reliable way to determine the presence of the virus.

One such way turned out to be a SARS-CoV-2 specific immunoglobulin G biophotonic sensor, which employed biofunctionalization to detect specific COVID-19 antibody selectivity. The sensors can be produced directly on the face of a single fiber optic, a single-mode fiber-28, and are sensitive enough to identify whether antibodies are present in a sample in around one minute’s time.

Optical coherence tomography (OCT) in dermatology

Previously, medical practitioners had to perform a biopsy to determine the presence of malignant tissue on the skin, but current optical coherence tomography technologies allow for a rapid, simple diagnosis without any skin excision. It can image skin to a depth of 2 mm, and resolution can be between 15 and 3 μm.

Biophotonics can also be employed during surgery to ensure full removal of problematic tissue. Nanoparticles functionalized with fluorescent dyes are applied to the skin to assemble in a particular kind of tissue. Any malignant tissue will glow when the skin is exposed to the relevant wavelengths of dye. This allows the surgeon to use epifluorescent microscopy and optical detection to decide what needs to be removed and what can be left. 

AI and biophotonic analysis

Deep learning algorithms are key for natural language processing and humanoid chatbots, and they are also central to how biophotonic data is processed. Just as machines can learn to comprehend human language, they can also learn to read the fingerprints of cells, organelles, and molecules. This enables the automation of basic diagnostics, and verification steps can be programmed into the system to ensure that nothing goes awry. 

At times, label-free identification of biological compounds will require analysis of a complex spectrum, which can be achieved by feed-forward neural networks (multilayer perceptrons, MLP) or recurrent neural networks (RNNs). These neural networks can compare test spectrums with detailed cataloged records to predict the probability of abnormal growths, disease, or the presence of other molecules. 

Deep learning algorithms can also conduct matrix multiplication containing millions of parameters, resolving complex equations that enable denoising, semantic segmentation, disease recognition, and even pseudostaining. Every day, breakthroughs in AI technologies are accelerating processing techniques and the potential of these analytical methods. 

Examples of advances in machine learning and biophotonics include AI solutions that can pull from extensive imaging data libraries to automatically detect the signs of infection in the inner ear. The AI-powered software can evaluate an OCT image of the ear captured by a portable device within half a minute. The data is then translated for diagnosis just as an expert would. 

Another example of AI in real-world applications is an intraoperative diagnosis system using stain-free, slide-free multimodal multi-photon microscopy. The data-rich images captured by biophotonic technology usually take a very long time to evaluate manually, but an AI system can generate a reliable, verifiable diagnosis in just a few minutes. 

Avantier is at the forefront of pushing the scientific envelope with advances in biophotonics. If you need a custom optical component, Avantier can manufacture exactly what you need, and a team of optical designers is on hand to help you determine what configurations will be optimally suited for your system. 

World Biophotonics Research Awards
Visit: biophotonicsresearch.com
Nominate Now: https://biophotonicsresearch.com/award-nomination/?ecategory=Awards&rcategory=Awardee 

Biophotonic (nano)structures: from fundamentals to emerging applications

 Biophotonics is a dynamic interdisciplinary field that merges biology, photonics, and optics to explore and manipulate biological systems through light. Its applications are particularly prominent in medical diagnostics, imaging, and therapy. Key uses of biophotonic (nano)structures include enhancing medical imaging and enabling biosensing to detect disease markers. In therapeutic contexts, these nanostructures show significant promise in photothermal and photodynamic therapies, improving imaging contrast and allowing for real-time monitoring of cellular processes. However, the field faces challenges such as fabrication complexities, scalability, biocompatibility, and integration with existing technologies.

For instance, limited biocompatibility can lead to adverse immune responses or toxicity, hindering their safe use in vivo, while scalability issues restrict the mass production of nanostructures with consistent quality, both of which are critical for clinical translation. Moreover, integrating these materials with existing medical devices or workflows often requires redesigning current platforms, slowing down adoption. Despite these obstacles, the future of biophotonics appears promising, especially with advancements in nanotechnology, including 3D printing and self-assembly, which could streamline production.

The potential integration of biophotonic nanostructures with emerging technologies like wearable devices and point-of-care diagnostics could revolutionize healthcare by facilitating continuous health monitoring and rapid disease detection. This review aims to provide a thorough examination of biophotonic nanostructures and their emerging applications in disease diagnosis, imaging, and therapy. Additionally, it will address the challenges and future directions of biophotonic research, enhancing our understanding of how these innovative technologies can tackle critical issues in modern medicine and deepen our knowledge of complex biological systems.

The purpose of this review is to explore the fundamentals, challenges, and future perspectives of biophotonic (nano)structures, highlighting their emerging applications and potential advancements.

Despite these advancements, several limitations remain in the development and application of biophotonic nanostructures. One major challenge is the scalability and cost-effectiveness of nanomaterial synthesis, particularly for clinical translation. Ensuring long-term biocompatibility and stability of biophotonic devices in complex biological environments is another critical issue. Indeed, the limited biocompatibility and biodegradability of these materials pose challenges for in vivo applications. Moreover, the integration of these devices into existing medical workflows requires standardized protocols and rigorous validation.35 Recent innovations in material science and device fabrication have addressed some of these challenges. For instance, researchers have explored naturally derived biomaterials, such as DNA, proteins, silk, and polysaccharides, which exhibit remarkable optical properties, biological compatibility, and degradability.

Green fluorescent protein (GFP) and riboflavin have been employed as gain media in biological lasers, while silk-based photonic structures have demonstrated potential for creating biocompatible optical devices.

The integration of biophotonic nanostructures with biological entities, such as cells, viruses, and tissues, has opened new avenues for designing hybrid systems.

These bio-inspired and biologically derived materials enable the construction of photonic devices that seamlessly interface with living systems, enhancing their functionality and adaptability for biomedical applications.

The development of self-assembled nanostructures and 3D-printed biocompatible materials has paved the way for scalable and customizable biophotonic devices. Hybrid systems that combine plasmonic NPs with responsive polymers offer tunable optical properties, enhancing their functionality for targeted diagnostics and therapy.

The aim of this review is to provide an overview about the recent advancements and emerging applications of biophotonic nanostructures via focusing on their applications in disease diagnosis, imaging, and therapy.

To this aim, the integration of biophotonic nanostructures in optoelectronics has been explored via highlighting their contributions to light-emitting diodes (LEDs), photodetectors, and other photonic devices. Furthermore, the challenges associated with their design, synthesis, and clinical translation have been discussed, offering insights into potential future directions for this rapidly evolving field. By bridging the gap between photonics, biology, and materials science, biophotonic nanostructures hold immense potential for developing healthcare and advancing our understanding of complex biological systems. Through this review, we aim to highlight the transformative impact of these nanostructures on science and technology, emphasizing their role in addressing some of the most pressing challenges in modern medicine.


World Biophotonics Research Awards
Visit: biophotonicsresearch.com
Nominate Now: https://biophotonicsresearch.com/award-nomination/?ecategory=Awards&rcategory=Awardee 

SPIE, the International Society for Optics and Photonics, Announces Its 2026 Society Awards

SPIE Announces Its 2026 Society Awards — Recognizing Excellence Across Optics & Photonics

SPIE, the International Society for Optics and Photonics, has revealed the winners of its prestigious 2026 Society Awards, honoring outstanding contributors to research, engineering, education, and community leadership in light-based science and technology. These annual honors celebrate both technical breakthroughs and sustained service to the global optics and photonics community — reinforcing SPIE’s role as a key advocate for innovation in fields from biomedical imaging to astronomical instrumentation.

The SPIE Gold Medal, the Society’s highest accolade, was awarded to Maryellen Giger for her pioneering work in computer-aided diagnosis and image analysis, significant influence on clinical translation, and mentorship of emerging medical-imaging scientists. Other major awardees include leaders in optical fabrication, scientific publishing, advanced light sources, and diversity outreach — illustrating the breadth of impact across both academic and industrial sectors.

Among other notable recognitions:

• The SPIE President’s Award acknowledged visionary leadership and service to optics education.

• The SPIE Mozi Award highlighted innovation in light sources with broad applications.

• Honors in biomedical optics, optical metrology, diffractive optics, and lithography underscored contributions to both fundamental science and enabling technologies.

• Early career and diversity outreach awards emphasized the Society’s commitment to fostering future talent and inclusive participation.

SPIE’s awards complement the broader community’s recognition efforts: 40 new SPIE Fellows were inducted in 2026, signifying exceptional technical achievement and professional contribution across optics and photonics disciplines. These Fellows — selected from leading academic, industry, and government institutions worldwide — illustrate the Society’s global reach and interdisciplinary impact.

Broader SPIE Community Activities and Awards

The Society’s awards are part of a wider landscape of recognition within the optics and photonics field:

• SPIE Prism Awards: Finalists in the 2026 Prism Awards — which spotlight commercialized innovations in photonics — include technologies spanning biophotonic instruments, quantum tech, lasers, and sensors. Winners will be celebrated at SPIE Photonics West in January 2026, showcasing products that are transforming markets from medical devices to advanced imaging systems.

• SPIE Startup Challenge: Earlier announcement of finalists for the 2026 SPIE Startup Challenge highlights early-stage companies with investable optics and photonics technologies — a key platform for translating research into commercial impact.
  
  

  Why SPIE Awards Matter

  As one of the most influential professional societies in light-based sciences and engineering, SPIE’s annual awards bring visibility to high-impact research, promote collaboration between academia and industry, and help shape the future of technologies driven by optics and photonics — from healthcare and manufacturing to communications and environmental sensing. Recognition by SPIE often reflects not only scientific excellence but also sustained commitment to community building and mentorship across generations of researchers and professionals.
  
  
  World Biophotonics Research Awards
  Visit: biophotonicsresearch.com
  Nominate Now: https://biophotonicsresearch.com/award-nomination/?ecategory=Awards&rcategory=Awardee